How long does it last?

<p>iDose® TR is designed for long-duration, continuous medication delivery. In clinical studies, about 8 out of 10 patients were drop-free 12 months after receiving the implant, with ongoing monitoring to ensure pressure stays on target.<a href="https://www.idosetr.com/support-and-resources/?utm_source=chatgpt.com"> Glaukos iDose® TR</a> Additional peer-reviewed data show durable IOP lowering and a reduced need for topical medications for 36 months after a single implant, though results vary by patient. Your specialist will track your eye pressure over time and discuss if/when a replacement implant or adjunct drops are appropriate</p>

iDose TR Glaucoma Treatment in Arizona

What is iDose® TR?

iDose® TR is a tiny implant containing travoprost, a medication commonly used to lower pressure inside the eye.

Instead of placing medication onto the surface of the eye every day with an eye drop, iDose TR is positioned inside the eye, where it gradually releases medication directly into the anterior chamber to relieve elevated eye pressure.

iDose TR is reduces intraocular pressure, or IOP, in patients with:

Open-angle glaucoma
Ocular hypertension

This new breakthrough in glaucoma treatment, helps doctors slow and/or prevent additional optic nerve damage from glaucoma.

Reduce The Drops: Patient Outcomes

Older adult applying eye drops at home, illustrating daily glaucoma treatment in Barnet Dulaney Perkins Eye Center’s article on interventional glaucoma care.

In the clinical trials, 81% of patients treated with iDose TR were completely free from topical eye-pressure-lowering medications at 12 months.

Longer-term research has also shown sustained reductions in eye pressure and topical medication use through three years in many patients.

However, iDose TR cannot guarantee that you will never need glaucoma drops again as every patient is different and no two eyes are alike.

Your glaucoma specialist will continue monitoring your eye pressure, optic nerve, and visual field after iDose treatment.

iDose® TR is a micro, FDA-approved intracameral implant that continuously releases a targeted dose of medication directly inside your eye for up to 4 years.

How The iDose® TR Procedure Works

1

Comfort & Prep

Your eye will be numb, and you’ll be comfortable throughout the procedure.

2

Mircoplacement

A eye surgeon places the implant through a tiny opening inside the eye.

3

Steady Delivery

The implant releases medication over time to help control IOP.

4

Follow-up

Routine visits track pressure and healing.

Abstract background representing eye care at BDP locations across Arizona.

Personalized Glaucoma Treatment at Barnet Dulaney Perkins

Glaucoma treatment has changed considerably in recent years. Daily eye drops are still valuable, but they are no longer the only way to manage eye pressure.

At Barnet Dulaney Perkins Eye Center, our glaucoma specialists evaluate your eye pressure, glaucoma severity, optic nerve health, lifestyle, previous treatments, and long-term risk before recommending a treatment plan.

Schedule Glaucoma Evaluation Call (602) 955-1000

Is iDose® TR right for me?

iDose TR may be considered for adults with open-angle glaucoma or ocular hypertension who need treatment to reduce eye pressure. Candidacy depends on your glaucoma severity, eye anatomy, previous treatments, current eye pressure, optic nerve health, and other factors before recommending iDose TR.

You may be a candidate if you:

Have difficulty remembering daily glaucoma drops
Have trouble physically putting drops into your eyes
Experience irritation or other problems with topical medications
Take several different glaucoma medications
Need additional help maintaining your target eye pressure

Comparing iDose® TR to Other Glaucoma Treatments

Daily Eye Drops

Daily use of medicated drops lowers eye pressure.

Pros: Widely available, non-surgical, customizable combinations.

Cons: Difficult for many patients to remember consistently, may cause burning, redness, or systemic side effects. Non-adherence is one of the leading causes of glaucoma progression.

Selective Laser Trabeculoplasty (SLT)

Uses laser energy to improve fluid drainage in the eye.

Pros: Quick, in-office procedure; can delay or reduce the need for drops.

Cons: Results may wear off over time; some patients still require drops or repeat treatments.

Learn More > SLT

Minimally Invasive Glaucoma Surgery (MIGS)

Small surgical implants or procedures improve eye fluid outflow.

Pros: Can be done with cataract surgery; effective for certain glaucoma stages.

Cons: Typically suited for mild to moderate glaucoma; still evolving in long-term outcomes.

Learn More > MIGS

iDose® TR (Sustained-Release Implant)

A tiny implant placed inside the eye releases medication continuously over months to years, reducing IOP without daily drops.

Pros: Long-term, consistent drug delivery; reduces or eliminates the need for drops; bypasses adherence issues; can be replaced when needed.

Cons: Requires a quick, in-office procedure; as with all implants, carries a small risk of surgical complications.

Tube Shunt

Lowers eye pressure by placing a small drainage tube in the eye that redirects fluid to a reservoir beneath the eyelid.

Pros: It can provide significant, long-term eye pressure reduction, especially for patients with advanced or difficult-to-control glaucoma.

Cons: It is a more invasive procedure with a longer recovery and greater risk of surgical complications than treatments such as eye drops, laser therapy, or iDose TR.

Learn More > Tube Shunt Surgery

Daily use of medicated drops lowers eye pressure.

Pros: Widely available, non-surgical, customizable combinations.

Cons: Difficult for many patients to remember consistently, may cause burning, redness, or systemic side effects. Non-adherence is one of the leading causes of glaucoma progression.

Uses laser energy to improve fluid drainage in the eye.

Pros: Quick, in-office procedure; can delay or reduce the need for drops.

Cons: Results may wear off over time; some patients still require drops or repeat treatments.

Learn More > SLT

Small surgical implants or procedures improve eye fluid outflow.

Pros: Can be done with cataract surgery; effective for certain glaucoma stages.

Cons: Typically suited for mild to moderate glaucoma; still evolving in long-term outcomes.

Learn More > MIGS

A tiny implant placed inside the eye releases medication continuously over months to years, reducing IOP without daily drops.

Pros: Long-term, consistent drug delivery; reduces or eliminates the need for drops; bypasses adherence issues; can be replaced when needed.

Cons: Requires a quick, in-office procedure; as with all implants, carries a small risk of surgical complications.

Lowers eye pressure by placing a small drainage tube in the eye that redirects fluid to a reservoir beneath the eyelid.

Pros: It can provide significant, long-term eye pressure reduction, especially for patients with advanced or difficult-to-control glaucoma.

Cons: It is a more invasive procedure with a longer recovery and greater risk of surgical complications than treatments such as eye drops, laser therapy, or iDose TR.

Learn More > Tube Shunt Surgery

iDose® TR Testimonials

Glaucoma Specialist at Barnet Dulaney Perkins

Neil J Atodaria, MD

Cataract, Glaucoma

Read Bio

Carlos Diaz, MD

Cataract, Glaucoma, LASIK, PRK, RLE Surgeon

Read Bio

Dan Eisenberg, MD

Glaucoma, Ophthalmologist

Read Bio

Christine Funke, MD

Cataract, Glaucoma

Read Bio

Sanjay Kamat, DO

Cataract, General Ophthalmology, Glaucoma

Read Bio

John D. Knippers, MD

Cataract, General Ophthalmology, Glaucoma, Surgeon

Read Bio

Andrew Rabinowitz, MD

Glaucoma

Read Bio

iDose TR FAQ

Many patients use significantly fewer drops after iDose, but some will still need additional medication. Your plan is personalized.

iDose® TR is designed for long-duration, continuous medication delivery. In clinical studies, about 8 out of 10 patients were drop-free 12 months after receiving the implant, with ongoing monitoring to ensure pressure stays on target. Glaukos iDose® TR Additional peer-reviewed data show durable IOP lowering and a reduced need for topical medications for 36 months after a single implant, though results vary by patient. Your specialist will track your eye pressure over time and discuss if/when a replacement implant or adjunct drops are appropriate

Yes, iDose can be placed independently or alongside cataract surgery in appropriate patients.

All procedures carry risks, such as temporary irritation, inflammation, pressure fluctuations, or the need for additional treatment. Your surgeon will review the benefits and risks for your eyes.

Most patients resume light activities quickly, following protection and care instructions.